Evidence map›Paper›PMID 25339810›Full record

ReviewWorld journal of gastroenterology2014

Improving outcomes in pancreatic cancer: key points in perioperative management.

José M Alamo, Luis M Marín, Gonzalo Suarez, Carmen Bernal, Juan Serrano, Lydia Barrera, Miguel A Gómez, Jordi Muntané, Francisco J Padillo

Registry-linked trialOpen access · greenAbstract readReview
In one paragraph

Review in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03340844 (Role of Circulating Tumor Cells), which is not on this map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03340844 nacompletednot on this mapstarted 2017, after this paper: background citation

Role of Circulating Tumor Cells (CTC´s) Spread During Pancreaticoduodenectomy in Metastasis and Survival Rates in Patients With Pancreatic and Periampullary Tumors

TypeinterventionalSponsorFundación Pública Andaluza para la gestión de la Investigación en SevillaRan2017 to 2023Enrolled86ConditionsPancreatic Tumor, Periampullary Carcinoma Resectable, Circulating Tumor Cells, MetastasisArmsNo Touch (NT), Superior Mesenteric Artery First (SMA)
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. A Multiomics Assessment of Preoperative Exercise in Pancreatic Cancer Survivors Receiving Neoadjuvant Therapy: A Case Series.Pathophysiology : the official journal of the International Society for Pathophysiology · 2024
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2017
    Article
  7. Article
  8. Perspectives in the treatment of pancreatic adenocarcinoma.World journal of gastroenterology · 2015
    Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

José M AlamoJosé M Álamo, Miguel A Gómez, Jordi Muntané, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREH o Ciberehd), Instituto de Salud Carlos III, 28029 Madrid, Spain.
Luis M MarínJosé M Álamo, Miguel A Gómez, Jordi Muntané, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREH o Ciberehd), Instituto de Salud Carlos III, 28029 Madrid, Spain.
Gonzalo SuarezJosé M Álamo, Miguel A Gómez, Jordi Muntané, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREH o Ciberehd), Instituto de Salud Carlos III, 28029 Madrid, Spain.
Carmen BernalJosé M Álamo, Miguel A Gómez, Jordi Muntané, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREH o Ciberehd), Instituto de Salud Carlos III, 28029 Madrid, Spain.
Juan SerranoJosé M Álamo, Miguel A Gómez, Jordi Muntané, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREH o Ciberehd), Instituto de Salud Carlos III, 28029 Madrid, Spain.
Lydia BarreraJosé M Álamo, Miguel A Gómez, Jordi Muntané, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREH o Ciberehd), Instituto de Salud Carlos III, 28029 Madrid, Spain.
Miguel A GómezJosé M Álamo, Miguel A Gómez, Jordi Muntané, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREH o Ciberehd), Instituto de Salud Carlos III, 28029 Madrid, Spain.
Jordi MuntanéJosé M Álamo, Miguel A Gómez, Jordi Muntané, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREH o Ciberehd), Instituto de Salud Carlos III, 28029 Madrid, Spain.
Francisco J PadilloJosé M Álamo, Miguel A Gómez, Jordi Muntané, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREH o Ciberehd), Instituto de Salud Carlos III, 28029 Madrid, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This review focused in the perioperative management of patients with pancreatic cancer in order to improve the outcome of the disease. We consider that the most controversial points in pancreatic cancer management are jaundice management, vascular resection and neo-adjuvant therapy. Preoperative biliary drainage is recommended only in patients with severe jaundice, as it can lead to infectious cholangitis, pancreatitis and delay in resection, which can lead to tumor progression. The development of a phase III clinical trial is mandatory to clarify the role of neo-adjuvant radiochemotherapy in pancreatic adenocarcinoma. Venous resection does not adversely affect postoperative mortality and morbidity, therefore, the need for venous resection should not be a contraindication to surgical resection in selected patients. The data on arterial resection alone, or combined with vascular resection at the time of pancreatectomy are more heterogeneous, thus, patient age and comorbidity should be evaluated before a decision on operability is made. In patients undergoing R0 resection, arterial resection can also be performed.

Indexed as

PancreatectomyPancreaticoduodenectomyAdenocarcinomaChemoradiotherapy, AdjuvantDrainageHumansNeoadjuvant TherapyPancreatic NeoplasmsPerioperative CarePostoperative ComplicationsRisk AssessmentRisk FactorsTreatment OutcomeVascular Surgical ProceduresNeo-adjuvant therapyObstructive jaundicePancreatic cancerPreoperative drainageVascular resection

Identifiers

PMID25339810
PMCPMC4202352
OpenAlexW1965122665

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.